You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 4, APRIL 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  REVIEW ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (23)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease

Lee J Hixson, MD; Catherine L. Kelley, PharmD; William N. Jones, MS; Craig D. Tuohy, MD

Arch Intern Med. 1992;152(4):717-723.


Abstract

Medical therapy for gastroesophageal reflux disease should entail a multistep approach. After life-style changes, many patients will require histamine2 receptor antagonists in conventional doses with repeated therapeutic courses, if not continuous maintenance. Prokinetic agents are potentially useful in those patients with impaired motor function of the esophageal or gastric smooth muscle. Combination therapy with histamine2 receptor antagonists and prokinetic agents or sucralfate provides modest healing benefit, if any, over that by histamine, receptor antagonists alone. For patients with more severe refractory disease, omeprazole has provided unequaled healing rates and accelerated symptomatic relief. High-dose (twofold or more standard dose) histamine2 receptor antagonist therapy may also heal highgrade esophagitis, but the reported experience is small. After healing is achieved, an attempt should generally be made to "step down" therapy to standard-dose histamine2 receptor antagonist as maintenance. Finding the least amount of drug to control symptoms and maintain the integrity of the esophageal mucosa would minimize cost and potential long-term risk.

(Arch Intern Med. 1992;152:717-723)



Author Affiliations

From the Medical (Drs Hixson and Touhy) and Pharmacy (Dr Kelley and Mr Jones) Services, Veterans Affairs Medical Center and Colleges of Medicine and Pharmacy, University of Arizona (Tucson).


Footnotes

Accepted for publication August 27, 1991.

Reprint requests to University Medical Center, GI Section, Room 6406, 1501 N Campbell Ave, Tucson, AZ 85724 (Dr Hixson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quality of life measurement in gastrointestinal and liver disorders
BORGAONKAR and IRVINE
Gut 2000;47:444-454.
ABSTRACT | FULL TEXT  

Gastroesophageal Reflux Disease and Asthma: Diagnosis and Management
Simpson
Arch Intern Med 1995;155:798-803.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.